Real-time PCR assay (qPCR) for the qualitative detection of human coronavirus SARS-CoV-2 from viral RNA extracted from nasopharyngeal (NP) swab specimens.
The world was introduced in December 2019 to a novel coronavirus detected in the Hubei province of China. This new coronavirus, deemed SARS-CoV-2, has in a matter of months evolved into a global health threat and is associated with significant morbidity and mortality tied to pneumonia. By the conclusion of March, SARS-CoV-2 has been classified as a global pandemic by the World Health Organization (WHO) and is responsible for nearly one million infections and the cause of more than 50,000 deaths.1
*For COVID-19 emergency use authorization only.
*For in vitro diagnostic use/Rx Only.
*The HDPCR™ SARS-CoV-2 Assay is validated with independent review by FDA pending.
For COVID-19 emergency use authorization only.
For in vitro diagnostic use/Rx Only.
The HDPCR™ SARS-CoV-2 Assay is validated with independent review by FDA pending.
A portion of test profits will be donated to support
healthcare providers and first responders
ChromaCode intends to do its part to assist the healthcare and larger community during this pandemic. ChromaCode will donate a portion of its net profits generated from the sale of its HDPCR™ SARS-CoV-2 assay.